---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-031335"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:10:41.475407+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics Q3 revenue $5.1M (down 83% YoY); net loss $1.4M vs prior-year income $11.5M

## Summary
- Revenue $5.1M, down from $30.1M a year ago; operating loss $6.5M vs income $13.6M.
- Net loss $1.4M ($0.04 loss per diluted share) vs net income $11.5M in Q3 2021.
- Adjusted EBITDA loss $4.1M; cash, equivalents, and marketable securities $86.5M.
- Repurchased 2.9M shares at avg $3.61; generated $1.1M operating cash flow in Q3.
- Co-Dx PCR Home platform nearing clinical evaluations; shipped Monkeypox test and appointed new CSO Dr. Mark Poritz.

## SEC filing metadata
- accession: 0001493152-22-031335
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315222031335/0001493152-22-031335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315222031335/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-031335
- JSON: https://secwatch.observer/filing/0001493152-22-031335.json
- Plain text: https://secwatch.observer/filing/0001493152-22-031335.txt

## Key facts
- Earnings Releases
  Co-Diagnostics, Inc. reported the third quarter ended September 30, 2022 results: revenue Revenue of $5.1 million, net income Net loss of $1.4 million, EPS loss of $0.04 per fully diluted share.
  - Period: the third quarter ended September 30, 2022
  - Revenue: Revenue of $5.1 million
  - Net income: Net loss of $1.4 million
  - EPS: loss of $0.04 per fully diluted share
  - Result: reported results
  source text: development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Financial Results: ● Revenue of $5.1 million, down from $30.1 million during the prior year period, but an increase of 1.4% from the current year second quarter ● Gross profit of $4.3 million, representing 84.9% of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1692415/000149315222031335/0001493152-22-031335-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.